Cardiovascular Associates
5656 Bee Caves Road, Suite M-300
Austin, TX 78746
Phone: (512) 807-3270
Fax: (855) 697-2500
Austin Cardiology Gastroenterology

Welcome to Little River Healthcare


In an environment of large, inefficient, hospital-based cardiology practices, Cardiovascular Associates’ mission is to provide a more traditional patient-physician relationship. ONE PATIENT, ONE DOCTOR.

Dr. Jonathan Sheinberg, Dr. Gary Foster, and Ross Brown, RN/CNS are committed to practicing state-of-the-art, evidence-based cardiovascular care that is also compassionate.

We pride ourselves on our exceptional training, our extensive experience, and our dedication to providing an individualized approach to cardiac care. We specialize in preventative cardiology, diagnosis and treatment of acute cardiac and vascular disorders, as well as long-term management of chronic disease.

By identifying patients at risk for heart disease, or those in the early stages of disease, we can partner with patients to design highly effective treatment strategies. We utilize the latest and most advanced technology in our echocardiography lab, our nuclear cardiology lab, and our vascular lab.

Our office is located in a beautiful setting adjacent to The Hospital at Westlake Medical Center. There is free parking.

At Cardiovascular Associates, we respect you and your time. Our medical and administrative staff are dedicated to patient care and patient satisfaction. We understand that the relationship between patient and doctor is sacred and lifelong. Our combination of compassion, experience, and technology allows us to develop this relationship to its fullest potential.

We strive toward making your visit with us pleasant and efficient. Learn more about us by clicking the menu to the right. You can schedule an appointment online, or call us to schedule an appointment or for any questions.

Cardiovascular Associates

5656 Bee Caves Road, Suite M-300,
Austin, TX 78746



8:00am – 5:00pm
Monday – Friday

Healthgrades | Facebook


Procedures Offered & Conditions Treated

• Coronary Artery Disease
Heart Attack
• Abdominal Heart Rhythms
• Congenital Heart Disease
• Heart Valve Disease
• Aorta Disease
• Marfan Syndrome
Congestive Heart Failure
• Arrythmias
• Vascular Disease
• Pericardial Disease

• Echocardiography
• Electrocardiogram
• Venous & Arterial Doppler
• Carotid Doppler
• Abdominal Aorta Ultrasound
• Renal Artery Ultrasound
• CT & CT Angiography
• Coronary Calcium Score
• Nuclear Cardiology
Stress Testing
• Pacemaker Assessment

• Heart Muscle Disease
• Pericarditis
• Aortic Aneurysm
• Truncus Arteriosus
• Heart Infection
Low Blood Pressure
• Stroke
• Metabolic Syndrome
• Coronary Heart Disease
• Deep Vein Thrombosis
High Cholesterol

• Palpitations
• Angina
• Atrial Fibrillation
• Coronary Artery Spasm
• Hypercholesterolaemia
• Carotid Artery Disease
• Aortic Valve Stenosis
• Coarctation of the Aorta
• Atrial Septal Defect
Heart Disease
High Blood Pressure


Click on a form title below to view or download the form.

Patient Information Form

Patient Consent Form

Drs. Sheinberg and Foster specialize in aggressive prevention and early detection of coronary artery disease. Using standard risk assessment tools, such as the Framingham Risk Calculator, basic cardiovascular risk can be determined. However, to more accurately predict risk, a more in-depth analysis must be undertaken.

Advanced lipid (cholesterol) testing can be utilized to evaluate not only the traditional concept of cholesterol quantity, but cholesterol quality as well. LDL (bad) and HDL (good) cholesterol can be further divided into subgroups based on their size and density.

Certain abnormally “sticky” LDL known as lipoprotein (a) Lp(a) is also measured as this can be an independent risk as well.

Besides cholesterol subset analysis, simple blood tests or even swabs of the cheek can yield vital genetic information that can predict heart blockages, aneurysms of the aorta, event response to certain medications including aspirin.

Your doctor can also use the latest technology to detect the earliest blockages. Early detection of heart disease can be undertaken with CT coronary calcium scoring, or more advanced blood tests that measure the inflammation or irritation the plaque causes on the blood vessel lining.

Prevention is a very active process. Besides blood testing and calcium scoring, often times a screening stress test will be performed to detect silent coronary disease. This type of test may be done if there are abnormalities in any of the screening assessments or an abnormal ECG.

Because so much is at stake and most heart disease is preventable, Cardiovascular Associates urges you to “Know your risk!”

Fatty Acids & Prostate Cancer

This statement is written with the help of one of the best fatty acid and fish oil experts in the country and supported by Cardiovascular Associates Director of Cardiology Dr. Jonathan Sheinberg. A paper was published in the Journal of the National Cancer Institute which was an update from the SELECT trial, which was a trial of selenium and vitamin E use for prostate cancer prevention. Plasma phospholipid omega 3 levels were measured in 834 men who eventually developed prostate cancer and in 1393 men who did not. They concluded that there was a 43 to 71% increase in the incidence of prostate cancer, particularly high grade tumors The same investigative group reached the same conclusion in a 2011 trial.
The omega 3 index (a way of measuring omega 3 levels in the blood) was not measured in this case. Instead, they reported EPA and DHA levels in plasma. The omega 3 index measures the EPA and DHA content of the red blood cell membrane, and a value above 8% is considered desirable and has been linked to lower cardiovascular event rates. In this trial, plasma levels were 3.62% in the no cancer control group, 3.66% in the total cancer group, 3.67% in the low grade cancer group, and 3.74% in the high grade prostate cancer group. In the opinion of the fatty acid expert, these differences are trivial and not clinically significant. In addition, the Omega 3 indexes that these values correlate with would be very low ….. somewhere between 3.1 and 4.7. In the Framingham study, mean Omega 3 indices of those participants not on fish oil supplementation were 5.2% and for those on supplements, 7.5%. Therefore, with the study design (which did not permit fish oil supplements apparently) and the extremely low omega 3 values, it is very unlikely that these participants were on fish oil supplements. Therefore, it is probably erroneous to conclude from this study that fish oil supplements cause prostate cancer.

Moreover, a 2010 metaanalysis concluded no relationship or a lower incidence between prostate cancer and fish intake and a 2001 and 2004 study reported lower incidence of prostate cancer among populations consuming more fish. Higher omega 3 intake has also been associated with better prostate cancer survival in several studies. The Japanese, which have much higher fish intake and omega 3 levels in the 12% range have substantially less prostate cancer than North Americans. Several major trials, Alpha Omega, GISSI, JELlS, Origin, Omega, and the Risk and Prevention trial have looked at the association between Omega 3 intake and cancer. These studies total about 78000 patients and in none of them was a positive association between Omega 3 intake and cancer found. Last, let’s look at overall mortality. Based on National Vital Statistics for deaths in men in the US, there were 28000 prostate cancer deaths and 207000 cardiovascular deaths. This means a 7-8 times higher chance of dying from cardiac causes than from prostate CA. If fish oil reduces the chances of cardiac death by 10% and increases the chances of prostate cancer by 50% (for the sake of argument), then US men are STILL 4 times more likely to die of heart disease (thus favoring the fish oil).